Research and Markets has announced the addition of the "Cervical Cancer-Market Insights, Epidemiology and Market Forecast - 2023 - United States" drug pipelines to their offering.
Cervical Cancer- Market Insights, Epidemiology and Market Forecast - 2023 - United States Report provides marketed drugs information of Cervical Cancer. It includes historical and forecasted epidemiology and market size of the Cervical Cancer of US for 2013-2023.
The market size of Cervical Cancer in United States is expected to grow at a Compound Annual Growth Rate of 0.68% and reach up to USD 96.28 million by 2023. The global market size of prophylaxis treatment for Cervical Cancer is expected to grow at a CAGR of 0.71% and reach up to USD 2210.9 Million by 2023.
Cervical Cancer needs to be focused more and more because it adversely affects younger women. It is the fourth most common cause of death among women. Cervical Cancer occurs due to the uncontrolled growth of healthy cells in cervix and forms cervical lesions. It spreads to other tissues such as vagina and uterus. Cervical Cancer is caused by inheritance of defects or mutation in genes.
Key Topics Covered:
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/t77gbt/cervical
View source version on businesswire.com: http://www.businesswire.com/news/home/20161017005494/en/Business Wire
Last updated on: 17/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.